March 13, 2024 8:12am

If the major indexes pull back soon, Tuesday's actionable stocks could struggle, at least temporarily as producer price data is due this week

Earnings: Sangamo Therapeutics (SGMO)and Solid Biosciences (SLDB)

Pre-open Indications: 3 Negative and 1 Positive Indications

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

 

Wednesday: The pre-open Dow futures are UP +0.09% or (+34 points), the S&P futures are UP +0.06% or (+3 points) as the Nasdaq futures are DOWM -0.05% or (-9 points)

Stock futures were low but up on Wednesday.

European markets were lower.

Asia-Pacific markets were mixed.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Tuesday indexes jumped with the Dow closing UP +235.83 points or +0.61%, as the S&P closed UP +57.33 points +1.12% and the Nasdaq closed UP +246.35 points or +1.54%

Tuesday’s rise in equity pricing, “came despite a consumer price index that showed inflation was mildly higher than expected in February, further clouding the outlook for when the Fed will start to cut interest rates. Notably, stocks jumped even as bond yields moved higher.” <CNBC>

Economic Data Docket:  MBA Mortgage Applications, week ending March 8 (+9.7%)

 

Tuesday’s night RegMed Investors (RMi) Closing Bell: “fresh inflation “number” upset daily share pricing response. The February CPI rose 0.4% as expected and higher than January's 0.3% rise. But the index was up 3.2% versus the 3.1% projected on an annual basis.” … https://www.regmedinvestors.com/articles/13368

 

Q1/24: march – 2 positive and 6 negative closes

  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

Negative Indication:

Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed down -$2.45 after Monday’s -$0.72 with a negative -$0.10 or -0.07% pre-open

Blueprint Medicine (BPMC) closed up +$0.23 with a negative -$0.69 or -0.77% pre-open indication.

BioLife Solutions (BLFS) closed down -$0.33 with a negative -$0.41 or -2.46% pre-open indication.

 

Positive Indications:

Tuesday, Monday, Friday, Thursday and last Wednesday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP) closed down -$1.52 after Monday’s -$2.10 after Friday’s -$0.45 with a positive +$0.14 or +0.19% pre-open

 

The BOTTOM LINE: believe it or not, I am at a loss for words …

I cannot think of anything to say … for once and even I am very surprised having written so much and so long.

Sometimes it’s better to say or write nothing than to write something wrong.

March has had 2 positive and 6 negative cell and gene therapy sector closes:

  • Tuesday closed with a negative close of 6 incliners, 27 decliners and 2 flats
  • (3/11) Monday closed with a negative close of 7 incliners, 28 decliners and 0 flat,
  • Friday closed with a negative close of 16 incliners, 19 decliners and 0 flat,
  • Thursday closed negative close of 16 incliners, 17 decliners and 2 flats
  • Wednesday closed positive with 21 incliners, 14 decliners and 0 flat,
  • Tuesday closed negative with 5 incliners, 29 decliners and 1 flat,
  • (3/4) Monday’s closed negative with 6 incliners, 27 decliners and 2 flats.
  • (3/1) Friday closed positive with 23 incliners, 10 decliners and 2 flats

 

The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

22 (of 35 covered companies) have reported …13 are left to release earnings of my covered group.

 

There is ALWAYS a however, the cell and gene therapy sector is DUE a rebound EVEN if it is due to algorithms and electronic trading RECOGNIZING risk and the oversold!!

I STILL reiterate, “Don't chase the cell and gene therapy sector.” Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

<span style="font-family:&quot;rom Friday" s="" market:",serif'=""> 

From Tuesday’s market:

  • The small-cap Russell 2000 fell a fraction, a third straight decline, though off session lows.
  • The 10-year Treasury yield rose 5 basis points to 4.15%.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.